Cart
sales@molnova.com
A09-003
CAS No. 2911646-14-3
A09-003( —— )
Catalog No. M37235 CAS No. 2911646-14-3
A09-003 is a novel cell cycle protein-dependent kinase-9 CDK-9 inhibitor.A09-003 inhibits the proliferation of a variety of leukemia cell lines and inhibits the increase of leukemia sequence-1 protein in myeloid cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2325 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameA09-003
-
NoteResearch use only, not for human use.
-
Brief DescriptionA09-003 is a novel cell cycle protein-dependent kinase-9 CDK-9 inhibitor.A09-003 inhibits the proliferation of a variety of leukemia cell lines and inhibits the increase of leukemia sequence-1 protein in myeloid cells.
-
DescriptionA09-003 is a CDK-9 inhibitor (IC50: 16 nM). A09-003 inhibits leukemia cell proliferation (IC50: 1.90, 0.86, 2.49, 1.84, 0.48 μM for BDCM, Molm-14, THP-1, U937, MV4-11 cells). A09-003 induces apoptosis and decreases Mcl-1 expression through Thr163 dephosphorylation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBCL | Apoptosis | CDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2911646-14-3
-
Formula Weight374.48
-
Molecular FormulaC23H26N4O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN=1C=CC(=CC1NC2=CC=CC(=C2)N3CCNCCC3)C=4C=CC=CC4OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sim KM, et al. A new cyclin-dependent kinase-9 inhibitor A09-003 induces apoptosis in acute myeloid leukemia cells with reduction of myeloid cell leukemia sequence-1 protein. Chem Biol Interact. 2023 Sep 1;382:110554.?
molnova catalog
related products
-
S55746
S55746 (BCL201, Servier-1) is a novel potent, selective, orally bioavailable inhibitor of BCL-2 with Ki of 1.3 nM.
-
BCL6-IN-8
BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface.
-
HA14-1
HA14-1 a small molecule, nonpeptidic Bcl-2 antagonist that binds Bcl-2 surface pocket with binding IC50 of 9 uM.
